Search Results - "Wistuba, Ignacio I"

Lung Cancer Biomarkers by Villalobos, Pamela, MD, Wistuba, Ignacio I., MD

“…The molecular characterization of lung cancer has changed the classification and treatment of these tumors, becoming an essential component of pathologic…”
Get full text

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial by Tawbi, Hussein A, Burgess, Melissa, Bolejack, Vanessa, Van Tine, Brian A, Schuetze, Scott M, Hu, James, D'Angelo, Sandra, Attia, Steven, Riedel, Richard F, Priebat, Dennis A, Movva, Sujana, Davis, Lara E, Okuno, Scott H, Reed, Damon R, Crowley, John, Butterfield, Lisa H, Salazar, Ruth, Rodriguez-Canales, Jaime, Lazar, Alexander J, Wistuba, Ignacio I, Baker, Laurence H, Maki, Robert G, Reinke, Denise, Patel, Shreyaskumar

“…Patients with advanced sarcomas have a poor prognosis and few treatment options that improve overall survival. Chemotherapy and targeted therapies offer…”
Get full text

A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee by Moreira, Andre L, Ocampo, Paolo S S, Xia, Yuhe, Zhong, Hua, Russell, Prudence A, Minami, Yuko, Cooper, Wendy A, Yoshida, Akihiko, Bubendorf, Lukas, Papotti, Mauro, Pelosi, Giuseppe, Lopez-Rios, Fernando, Kunitoki, Keiko, Ferrari-Light, Dana, Sholl, Lynette M, Beasley, Mary Beth, Borczuk, Alain, Botling, Johan, Brambilla, Elisabeth, Chen, Gang, Chou, Teh-Ying, Chung, Jin-Haeng, Dacic, Sanja, Jain, Deepali, Hirsch, Fred R, Hwang, David, Lantuejoul, Sylvie, Lin, Dongmei, Longshore, John W, Motoi, Noriko, Noguchi, Masayuki, Poleri, Claudia, Rekhtman, Natasha, Tsao, Ming-Sound, Thunnissen, Erik, Travis, William D, Yatabe, Yasushi, Roden, Anja C, Daigneault, Jillian B, Wistuba, Ignacio I, Kerr, Keith M, Pass, Harvey, Nicholson, Andrew G, Mino-Kenudson, Mari

“…A grading system for pulmonary adenocarcinoma has not been established. The International Association for the Study of Lung Cancer pathology panel evaluated a…”
Get more information

Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues by Parra, Edwin R., Uraoka, Naohiro, Jiang, Mei, Cook, Pamela, Gibbons, Don, Forget, Marie-Andrée, Bernatchez, Chantale, Haymaker, Cara, Wistuba, Ignacio I., Rodriguez-Canales, Jaime

“…Immune-profiling is becoming an important tool to identify predictive markers for the response to immunotherapy. Our goal was to validate multiplex…”
Get full text

Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion by Peng, David H., Rodriguez, Bertha Leticia, Diao, Lixia, Chen, Limo, Wang, Jing, Byers, Lauren A., Wei, Ying, Chapman, Harold A., Yamauchi, Mitsuo, Behrens, Carmen, Raso, Gabriela, Soto, Luisa Maren Solis, Cuentes, Edwin Roger Parra, Wistuba, Ignacio I., Kurie, Jonathan M., Gibbons, Don L.

“…Tumor extracellular matrix has been associated with drug resistance and immune suppression. Here, proteomic and RNA profiling reveal increased collagen levels…”
Get full text

Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non–small cell lung cancer by Shien, Kazuhiko, Papadimitrakopoulou, Vassiliki A, Wistuba, Ignacio I

“…Highlights • PD-1 pathway inhibitors have shown remarkable antitumor activity in NSCLC. • PD-L1 expression and mutational loads in tumor cells are predictive…”
Get full text

Diagnosis and Molecular Classification of Lung Cancer by Rodriguez-Canales, Jaime, Parra-Cuentas, Edwin, Wistuba, Ignacio I

“…Lung cancer is a complex disease composed of diverse histological and molecular types with clinical relevance. The advent of large-scale molecular profiling…”
Get more information

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy by Lee, Heng-Huan, Wang, Ying-Nai, Xia, Weiya, Chen, Chia-Hung, Rau, Kun-Ming, Ye, Leiguang, Wei, Yongkun, Chou, Chao-Kai, Wang, Shao-Chun, Yan, Meisi, Tu, Chih-Yen, Hsia, Te-Chun, Chiang, Shu-Fen, Chao, K.S. Clifford, Wistuba, Ignacio I., Hsu, Jennifer L., Hortobagyi, Gabriel N., Hung, Mien-Chie

“…Reactivation of T cell immunity by PD-1/PD-L1 immune checkpoint blockade has been shown to be a promising cancer therapeutic strategy. However, PD-L1…”
Get full text

A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition by Mak, Milena P, Tong, Pan, Diao, Lixia, Cardnell, Robert J, Gibbons, Don L, William, William N, Skoulidis, Ferdinandos, Parra, Edwin R, Rodriguez-Canales, Jaime, Wistuba, Ignacio I, Heymach, John V, Weinstein, John N, Coombes, Kevin R, Wang, Jing, Byers, Lauren Averett

“…We previously demonstrated the association between epithelial-to-mesenchymal transition (EMT) and drug response in lung cancer using an EMT signature derived…”
Get full text

Expression of PD-1 and PD-L1 in thymic epithelial neoplasms by Weissferdt, Annikka, Fujimoto, Junya, Kalhor, Neda, Rodriguez, Jaime, Bassett, Roland, Wistuba, Ignacio I, Moran, Cesar A

“…Thymic epithelial neoplasms are rare tumors that are difficult to diagnose and treat. Programmed death 1 (PD-1) receptor and its ligand (PD-L1) are expressed…”
Get full text

ZEB1 drives epithelial-to-mesenchymal transition in lung cancer by Larsen, Jill E, Nathan, Vaishnavi, Osborne, Jihan K, Farrow, Rebecca K, Deb, Dhruba, Sullivan, James P, Dospoy, Patrick D, Augustyn, Alexander, Hight, Suzie K, Sato, Mitsuo, Girard, Luc, Behrens, Carmen, Wistuba, Ignacio I, Gazdar, Adi F, Hayward, Nicholas K, Minna, John D

“…Increased expression of zinc finger E-box binding homeobox 1 (ZEB1) is associated with tumor grade and metastasis in lung cancer, likely due to its role as a…”
Get full text

Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing by Zhang, Jianjun, Fujimoto, Junya, Zhang, Jianhua, Wedge, David C., Song, Xingzhi, Zhang, Jiexin, Seth, Sahil, Chow, Chi-Wan, Cao, Yu, Gumbs, Curtis, Gold, Kathryn A., Kalhor, Neda, Little, Latasha, Mahadeshwar, Harshad, Moran, Cesar, Protopopov, Alexei, Sun, Huandong, Tang, Jiabin, Wu, Xifeng, Ye, Yuanqing, William, William N., Lee, J. Jack, Heymach, John V., Hong, Waun Ki, Swisher, Stephen, Wistuba, Ignacio I., Futreal, P. Andrew

“…Cancers are composed of populations of cells with distinct molecular and phenotypic features, a phenomenon termed intratumor heterogeneity (ITH). ITH in lung…”
Get full text

CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade by Chen, Limo, Diao, Lixia, Yang, Yongbin, Yi, Xiaohui, Rodriguez, B Leticia, Li, Yanli, Villalobos, Pamela A, Cascone, Tina, Liu, Xi, Tan, Lin, Lorenzi, Philip L, Huang, Anfei, Zhao, Qiang, Peng, Di, Fradette, Jared J, Peng, David H, Ungewiss, Christin, Roybal, Jonathon, Tong, Pan, Oba, Junna, Skoulidis, Ferdinandos, Peng, Weiyi, Carter, Brett W, Gay, Carl M, Fan, Youhong, Class, Caleb A, Zhu, Jingfen, Rodriguez-Canales, Jaime, Kawakami, Masanori, Byers, Lauren Averett, Woodman, Scott E, Papadimitrakopoulou, Vassiliki A, Dmitrovsky, Ethan, Wang, Jing, Ullrich, Stephen E, Wistuba, Ignacio I, Heymach, John V, Qin, F Xiao-Feng, Gibbons, Don L

“…Although treatment with immune checkpoint inhibitors provides promising benefit for patients with cancer, optimal use is encumbered by high resistance rates…”
Get more information

Fatty Acid Oxidation Mediated by Acyl-CoA Synthetase Long Chain 3 Is Required for Mutant KRAS Lung Tumorigenesis by Padanad, Mahesh S., Konstantinidou, Georgia, Venkateswaran, Niranjan, Melegari, Margherita, Rindhe, Smita, Mitsche, Matthew, Yang, Chendong, Batten, Kimberly, Huffman, Kenneth E., Liu, Jingwen, Tang, Ximing, Rodriguez-Canales, Jaime, Kalhor, Neda, Shay, Jerry W., Minna, John D., McDonald, Jeffrey, Wistuba, Ignacio I., DeBerardinis, Ralph J., Scaglioni, Pier Paolo

“…KRAS is one of the most commonly mutated oncogenes in human cancer. Mutant KRAS aberrantly regulates metabolic networks. However, the contribution of cellular…”
Get full text

Comprehensive Computational Pathological Image Analysis Predicts Lung Cancer Prognosis by Luo, Xin, Zang, Xiao, Yang, Lin, Huang, Junzhou, Liang, Faming, Rodriguez-Canales, Jaime, Wistuba, Ignacio I, Gazdar, Adi, Xie, Yang, Xiao, Guanghua

“…Pathological examination of histopathological slides is a routine clinical procedure for lung cancer diagnosis and prognosis. Although the classification of…”
Get more information

Comprehensive T cell repertoire characterization of non-small cell lung cancer by Reuben, Alexandre, Zhang, Jiexin, Chiou, Shin-Heng, Gittelman, Rachel M., Li, Jun, Lee, Won-Chul, Fujimoto, Junya, Behrens, Carmen, Liu, Xiaoke, Wang, Feng, Quek, Kelly, Wang, Chunlin, Kheradmand, Farrah, Chen, Runzhe, Chow, Chi-Wan, Lin, Heather, Bernatchez, Chantale, Jalali, Ali, Hu, Xin, Wu, Chang-Jiun, Eterovic, Agda Karina, Parra, Edwin Roger, Yusko, Erik, Emerson, Ryan, Benzeno, Sharon, Vignali, Marissa, Wu, Xifeng, Ye, Yuanqing, Little, Latasha D., Gumbs, Curtis, Mao, Xizeng, Song, Xingzhi, Tippen, Samantha, Thornton, Rebecca L., Cascone, Tina, Snyder, Alexandra, Wargo, Jennifer A., Herbst, Roy, Swisher, Stephen, Kadara, Humam, Moran, Cesar, Kalhor, Neda, Zhang, Jianhua, Scheet, Paul, Vaporciyan, Ara A., Sepesi, Boris, Gibbons, Don L., Robins, Harlan, Hwu, Patrick, Heymach, John V., Sharma, Padmanee, Allison, James P., Baladandayuthapani, Veera, Lee, Jack J., Davis, Mark M., Wistuba, Ignacio I., Futreal, P. Andrew, Zhang, Jianjun

“…Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better…”
Get full text

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs by Kris, Mark G, Johnson, Bruce E, Berry, Lynne D, Kwiatkowski, David J, Iafrate, A. John, Wistuba, Ignacio I, Varella-Garcia, Marileila, Franklin, Wilbur A, Aronson, Samuel L, Su, Pei-Fang, Shyr, Yu, Camidge, D. Ross, Sequist, Lecia V, Glisson, Bonnie S, Khuri, Fadlo R, Garon, Edward B, Pao, William, Rudin, Charles, Schiller, Joan, Haura, Eric B, Socinski, Mark, Shirai, Keisuke, Chen, Heidi, Giaccone, Giuseppe, Ladanyi, Marc, Kugler, Kelly, Minna, John D, Bunn, Paul A

“…IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung…”
Get full text

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer by Lissanu Deribe, Yonathan, Sun, Yuting, Terranova, Christopher, Khan, Fatima, Martinez-Ledesma, Juan, Gay, Jason, Gao, Guang, Mullinax, Robert A., Khor, Tin, Feng, Ningping, Lin, Yu-Hsi, Wu, Chia-Chin, Reyes, Claudia, Peng, Qian, Robinson, Frederick, Inoue, Akira, Kochat, Veena, Liu, Chang-Gong, Asara, John M., Moran, Cesar, Muller, Florian, Wang, Jing, Fang, Bingliang, Papadimitrakopoulou, Vali, Wistuba, Ignacio I., Rai, Kunal, Marszalek, Joseph, Futreal, P. Andrew

“…Lung cancer is a devastating disease that remains a top cause of cancer mortality. Despite improvements with targeted and immunotherapies, the majority of…”
Get full text

Game of clones: Battles in the field of carcinogenesis by Rahal, Zahraa, Sinjab, Ansam, Wistuba, Ignacio I., Kadara, Humam

“…Recent advances in bulk sequencing approaches as well as genomic decoding at the single-cell level have revealed surprisingly high somatic mutational burdens…”
Get full text

The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer by Smeltzer, Matthew P, Wynes, Murry W, Lantuejoul, Sylvie, Soo, Ross, Ramalingam, Suresh S, Varella-Garcia, Marileila, Meadows Taylor, Meghan, Richeimer, Kristin, Wood, Kelsey, Howell, Kristen E, Dalurzo, Mercedes Lilana, Felip, Enriqueta, Hollenbeck, Gina, Kerr, Keith, Kim, Edward S, Mathias, Clarissa, Pacheco, Jose, Postmus, Pieter, Powell, Charles, Tsuboi, Masahiro, Wistuba, Ignacio I, Wakelee, Heather A, Belani, Chandra P, Scagliotti, Giorgio V, Hirsch, Fred R

“…Access to targeted therapies for lung cancer depends on the accurate identification of patients' biomarkers through molecular testing. The International…”
Get more information